Menu
Global market with high growth
The global prostate cancer market is growing and is estimated to be worth USD 100 billion by 2026. More and more men are affected due to increased life expectancy.
A real clinical need
There is currently no established effective treatment for patients with recurrent prostate cancer. This is our first priority indication.
A new treatment option
Our treatment system has potential to replace surgery and/or hormone therapy, to provide fewer side effects and a give the patient better quality of life.
Health economic viability
Our treatment method is designed to be less resource-consuming by providing a one-off treatment, unlikecontinuous hormone therapy, and by avoiding extensive risky surgery.
Attractive business model with continuous revenue streams
The system is placed at the customer’s site for a low cost, providing a reduced barrier to entry. Recurring revenue is generated through the sale of sterile disposable equipment, with customers paying per treatment.
Potential to develop treatment for more cancer diagnoses
The treatment system has potential to be suitable for several types of internal solid tumors, not just our initial indication, recurrent prostate cancer.
SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.
We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.